Mitobronitol (1,6-dibromo-1,6-dideoxy-D-mannitol, Dibromomannitol) is a brominated analog of mannitol, it is one of a number of carbohydrate derivatives which have exhibited varying degrees of antineoplastic activity. Hungarian investigators first synthesized a series of cytostatic carbohydrate derivatives over two decades ago. Dibromomannitol (DBM) and its conformational isomer dibromodulcitol (DBD) have undergone extensive clinical investigation in the United States. DBD differs from its conformational isomer DBM in activity spectrum, having significant activity against solid tumors and its relative lack of nephrotoxicity. Clinical trials with DBM in the U.S. were carried out mainly in CML; the trials were based on foreign reports of activity in this tumor type. Only the oral form was available for clinical use.